EUCTR2016-001160-11-Outside-EU/EEA进行中（未招募）1 期
An Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Tacrolimus Ointment in the Treatment of Atopic Dermatitis in Pediatric Patients
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Children 2-10 years of age;
- •- Mild to severe atopic dermatitis.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 170
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Skin disorder other than atopic dermatitis;
- •- Previous treatment with tacrolimus ointment in a clinical study;
- •- Known diagnosis or history of cancer, including skin cancer, or human immunodeficiency virus (HIV);
- •- Clinically infected atopic dermatitis.
研究者
相似试验
进行中（未招募）
1 期
An Open-label, Multicenter Study Evaluating the Efficacy and Safety of 24 or 48 weeks pegylated interferon alfa-2a 40 kD (PEGASYS®) Combination Therapy with Ribavirin (Copegus®) in Patients with Chronic Hepatitis C Genotype 2 or 3 Infection who Previously Have Relapsed After a Minimum of 12 Weeks and a Maximum of 24 Weeks of Therapy with pegylated interferon and Ribavirin - RelapCchronic hepatitis C (CHC) virus infection genotype 2 or 3 who responded during (i.e. had HCV-RNA < 50 IU/mL at the end of previous therapy), but relapsed after (i.e. had detectable HCV-RNA after the end of prior treatment) previous therapy with pegylated interferon and ribavirin given for at least 12 weeks and at most 24 weeks.EUCTR2006-003409-18-SESahlgrenska University Hospital, Östra100
进行中（未招募）
不适用
An Open-label, Multicenter Study Evaluating the Efficacy and Safety of 24 or 48 weeks pegylated interferon alfa-2a 40 kD (PEGASYS®) Combination Therapy with Ribavirin (Copegus®) in Patients with Chronic Hepatitis C Genotype 2 or 3 Infection who Previously Have Relapsed After a Minimum of 12 Weeks and a Maximum of 24 Weeks of Therapy with pegylated interferon and Ribavirin - RelapCchronic hepatitis C (CHC) virus infection genotype 2 or 3 who responded during (i.e. had HCV-RNA < 50 IU/mL at the end of previous therapy), but relapsed after (i.e. had detectable HCV-RNA after the end of prior treatment) previous therapy with pegylated interferon and ribavirin given for at least 12 weeks and at most 24 weeks.MedDRA version: 9.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2006-003409-18-FIHUS100
进行中（未招募）
1 期
An Open-label, Multicenter Study Evaluating the Efficacy and Safety of 24 or 48 weeks pegylated interferon alfa-2a 40 kD (PEGASYS®) Combination Therapy with Ribavirin (Copegus®) in Patients with Chronic Hepatitis C Genotype 2 or 3 Infection who Previously Have Relapsed After a Minimum of 12 Weeks and a Maximum of 24 Weeks of Therapy with pegylated interferon and Ribavirin - RelapCChronic hepatitis C (CHC) genotype 2 or 3 infection with previous response relapseEUCTR2006-003409-18-DKRelap-C study Steering Commitee100
进行中（未招募）
1 期
A Study to evaluate the effect and safety of experimental drugs ABT-493/ABT-530 in adults with Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)Hepatitis C Virus InfectionHuman Immunodeficiency Virus InfectionChronic Hepatitis CCompensated Cirrhosis and Non-cirrhoticsEUCTR2015-005577-20-PLAbbVie Deutschland GmbH & Co. KG160
进行中（未招募）
1 期
A Study to evaluate the effect and safety of experimental drugs ABT-493/ABT-530 in adults with Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)EUCTR2015-005577-20-DEAbbVie Deutschland GmbH & Co. KG160